Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies

Shin Foong Ngiow 1,2,3* and Arabella Young 3,4†

1 Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, United States, 2 Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States, 3 Department of Immunology, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia, 4 Diabetes Center, University of California, San Francisco, San Francisco, CA, United States

The clinical success of cancer immunotherapies targeting PD-1 and CTLA-4 has ignited a substantial research effort to improve our understanding of tumor immunity. Recent studies have revealed that the immune contexture of a tumor influences therapeutic response and survival benefit for cancer patients. Identifying treatment modalities that limit immunosuppression, relieve T cell exhaustion, and potentiate effector functions in the tumor microenvironment (TME) is of much interest. In particular, combinatorial therapeutic approaches that re-educate the TME by limiting the accumulation of immunosuppressive immune cells, such as Foxp3 regulatory T cells (Tregs) and tumor-associated macrophages (TAMs), while promoting CD8+ and CD4+ effector T cell activity is critical. Here, we review key approaches to target these immunosuppressive immune cell subsets and signaling molecules and define the impact of these changes to the tumor milieu. We will highlight the preclinical and clinical evidence for their ability to improve anti-tumor immune responses as well as strategies and challenges for their implementation. Together, this review will provide understanding of therapeutic approaches to efficiently shape the TME and reinvigorate the immune response against cancer.

Keywords: tumor-associated myeloid cells, regulatory T cells (Tregs), natural killer T (NKT) cells, mucosal-associated invariant T (MAIT) cells, adenosine, transforming growth factor (TGF)β, prostaglandin, immune toxicity

INTRODUCTION

The clinical validation of key conceptual developments in the field of tumor immunology has engendered much interest in strategies to initiate immune cell function within the tumor microenvironment (TME). Central to effective anti-tumor immunity induced by cancer immunotherapies is the ability to re-educate and re-activate immune effector and cytotoxic T cells to eliminate cancer cells. As such, immunotherapies targeting T cell immune checkpoint receptors cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and/or programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) have ascended to first-line therapies for a number of solid malignancies (1). Combinatorial anti-tumor efficacy of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) in advanced stage melanoma and renal cell carcinoma (RCC) highlights...
the importance of targeting multiple immune pathways to unleash a more robust anti-tumor immune response (2, 3). In addition, FDA-approval of pembrolizumab (anti-PD-1) for the treatment of microsatellite instability-hi (MSI-h) and deficient DNA mismatch repair (dMMR) tumors, the first cancer-site agnostic treatment approval, as well as the correlation between tumor mutational burden and survival outcome sheds light on the significance of tumor genetics in initiating an immune response (4–6). Similarly, PD-L1 status has been shown to impact therapeutic outcome to PD-1/PD-L1 targeting immunotherapies (7). This highlights that a better understanding of the immune contexture and its interaction with surrounding tumor, stroma, and their derivatives (e.g., chemokines and other soluble factors) is crucial to developing novel therapeutic targets to efficiently shape and re-condition the TME, reinvigorating the immune response against cancer.

Functional anti-tumor immunity relies on both the quality (effector and cytotoxic function) and quantity (numbers and localization) of tumor-infiltrating lymphocytes (TILs) in the TME. Targeting CTLA-4 and PD-1 non-redundantly mobilizes and activates alternate T cell components, with CTLA-4 shown to inhibit priming and generation of antigen-specific T cells in the lymph nodes whereas PD-1 limits CD8+ T cell numbers in the tissue, for superior anti-tumor outcomes (8, 9). The concept of targeting two or more non-redundant immune regulatory pathways for enhanced anti-tumor immunity is not limited to adaptive immunity. A combination of anti-DR5, anti-CD40, and anti-CD137 agonistic antibodies aiming to induce apoptosis in tumor cells, activate antigen presenting cells (innate immunity), and co-stimulate CD8+ T cells (adaptive immunity), respectively, has been shown to eradicate both established transplantable and spontaneous tumors (10). Similarly, it has been shown that a combination of recombinant interleukin (IL)-2, anti-PD-1, a tumor-antigen targeting antibody, and an additional vaccine targeting three individual tumor antigens is able to eradicate a poorly immunogenic murine melanoma, via the activation of both innate and adaptive immunity (11). Here, we review key approaches to target pathways alternative to mainstream T cell checkpoint receptors to re-educate the TME and alleviate immune suppression and highlight challenges for therapy selection and implementation in the clinic.

| Abbreviations: | A2AR, A2A adenosine receptor; APCs, antigen presenting cells; CSF1, colony stimulating factor 1; CSF1R, colony stimulating factor 1 receptor; COX, cyclooxygenase; CTLA-4, cytotoxic T-lymphocyte associated protein 4; dMMR, deficient DNA mismatch repair; EZH2, enhancer of zeste homolog 2; FLT3L, FMS-like tyrosine kinase 3 ligand; IDO, indoleamine 2,3-dioxygenase; IFN, interferon; irAEs, immune-related adverse events; IL, interleukin; MAIT, mucosal-associated invariant T; MSI-h, microsatellite instability-hi; NKT, natural killer T; NRP1, neuropilin-1; NSCLC, non-small cell lung cancer; PDAC, pancreatic ductal adenocarcinoma; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; PMN-MDSC, polymorphonuclear myeloid-derived suppressor cells; PTSG2, prostaglandin-endoperoxide synthase 2; RCC, renal cell carcinoma; Tregs, regulatory T cells; TAMs, tumor-associated macrophages; TGF, transforming growth factor; TILs, tumor-infiltrating lymphocytes; TME, tumor microenvironment; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor. |

**IMPROVING TUMOR CONTROL WITH MYELOID CELLS IN THE TME**

Myeloid cells predominate the TME and in many cases evolve to display an immunosuppressive phenotype and ineffective antigen presenting cells (APCs) due to the inflammatory milieu (Figure 1). Tumor-associated macrophages (TAMs) are innate immune cells of heterogeneous origins that have been shown to accumulate in the TME as tumors progress (12–14). The presence of immunosuppressive TAMs can interfere with T cell-mediated anti-tumor immune responses (15, 16). Given the absence of a universal definition for TAMs, we have listed relevant markers used in individual studies. It has been reported that an accumulation of monocyte-derived TAMs (CD11b/ MHC-II+/lo) positively correlates with the proportion of tumor-infiltrating exhausted PD-1+ CD8+ T cells in a mouse model of mammary cancer (12), illustrating a potential mechanism by which TAMs promote tumor escape by modulating the CD8+ T cell response. More recently, it has been shown that TAMs (CD11b+ MHC-II+) are capable of stripping anti-PD-1 bound to PD-1+ T cells by binding to the antibody Fc domain, abrogating the anti-tumor activity of this immune checkpoint inhibitor (17). It remains unclear if a similar resistance mechanism also exists in the context of anti-PD-L1 therapy. However, in preclinical mouse models Fc engagement is critical for anti-PD-L1 (clone 10F.9G2) therapeutic efficacy by enabling depletion of immunosuppressive TAMs (CD11b+ F4/80+) (18). Therefore, defining the functionality of an antibodies Fc region for optimal therapeutic activity in the context of both T cells and myeloid cells is an important consideration. Additionally, modulating TAMs via targeted depletion, inhibiting active migration, and promoting activation and differentiation, as a means to re-educate the TME may increase permissiveness to immune checkpoint inhibitor therapy.

The colony stimulating factor 1 (CSF1)/CSF1 receptor (CSF1R) axis is crucial for TAM differentiation (19). Selective depletion of TAMs by targeting CSF1R using monoclonal antibodies or small molecule inhibitors has been shown to restrict CSF1R+ TAM accumulation in the TME, leading to reduced tumor growth in a number of mouse models (20–23). Depletion of CSF1R+ TAMs demonstrated efficacy in improving a wide range of existing cancer therapies, including chemotherapy, oncogene-targeted therapy, and immunotherapy (21, 23, 24). In preclinical BRAF-mutant melanoma, co-administration of PLX3397 (CSF1R inhibitor) together with PLX4720 (mutant BRAF inhibitor) effectively sensitizes a PD-1-resistant tumor model to anti-PD-1/PD-L1 therapies (23). However, CSF1R inhibition induces the expansion of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) that may abrogate the efficacy of combination CSF1R inhibition and anti-PD-1 treatment (23, 25). Evidence that targeting CSF1R and CXCR2 signaling to inhibit TAM and PMN-MDSC expansion, respectively, alongside anti-PD-1 facilitates improved anti-tumor immune responses than either doublet combination (25). Alternatively, targeting the CCL2/CXCR2 axis, a key chemokine pathway involved in macrophage migration to inflammatory sites, to limit their entry into the TME.
enabled numerical and functional improvement of intratumoral lymphocyte infiltrate (26–29). Wu et al. demonstrated improved survival outcomes in cutaneous T-cell lymphoma-bearing mice treated with a CCR2 inhibitor and anti-PD-1 (28). Collectively, these studies highlight that inhibition of pro-tumor TAMs in the TME reinvigorates the anti-PD-1-driven T cell response. Of note, a phase I/II clinical trial accessing the combinatorial effect of nivolumab, GVAX (a cancer vaccine expressing GM-CSF) and BMS-813160 (a CCR2/CCR5 dual antagonist) in pancreatic ductal adenocarcinoma (PDAC) is currently underway (NCT03767582).

It is worth highlighting that not all tumor-infiltrating myeloid cells promote tumor growth. The production of CXCL9 and CXCL10, predominantly by TAMs (CD11b+ Ly6Cint CD11c+ F4/80+), enhances CD8+ T cell infiltration and tumor control in response to combination anti-PD-1 and anti-CTLA-4 in a mouse model of mammary adenocarcinoma (30). High production of these chemokines within the TME is associated with better

![Diagram](https://example.com/diagram.png)

**FIGURE 1** | Immunosuppressive targets in the tumor microenvironment. Re-educating the tumor microenvironment to improve the response to cancer immunotherapies can be performed through targeting many cellular and immunosuppressive factors. These include (A) tumor-infiltrating myeloid cells such as tumor-associated macrophages and dendritic cells, (B) tumor-infiltrating Tregs, and (C) tumor-derived immunosuppressive factors. Therapeutically altering these immunomodulatory components may promote anti-tumor immunity either alone or synergize with FDA-approved immune checkpoint inhibition.
survival outcomes in melanoma patients receiving combination treatment (30). In light of these findings, reprogramming these innate immune cell subsets may be beneficial due to their antigen presenting properties promoting infiltration of an effective anti-tumor T cell response. In KPC (LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre) PDAC TAMs (CD11b+ Gr1− F4/80+) enable T cell exclusion and consequently, resistance to immune checkpoint therapy is likely driven by the absence of effector T cells that can be modulated (31, 32). Independent studies of mouse pancreatic models have demonstrated the remodeling activity of the agonistic CD40 antibody by overcoming T cell exclusion in the TME, leading to improved therapeutic response to anti-CTLA-4, and/or anti-PD-1 (33–35). Using a T cell-rich but anti-PD-1 resistant mammary carcinoma model, we have recently demonstrated that IL-12 induced by an agonistic CD40 antibody could render terminally exhausted PD-1hi tumor-infiltrating CD8+ T cells into their PD-1int progenitor state (36), leading to improved anti-tumor immunity in response to anti-PD-1 following sensitization by anti-CD40 agonism.

An additional therapeutic approach to re-educate the TME and bolster the efficacy of immune checkpoint therapy is combination treatment with FMS-like tyrosine kinase 3 ligand (FLT3L) and poly I:C treatment, to expand and enhance maturation of anti-tumor CD103+ dendritic cells (DCs) resulting in a dramatic increase of intratumoral T cells (37). Notably, T cell-activating IL-12 producing CD103+ DCs diminish over time (37–41), suggesting that they may facilitate tumor control during tumor initiation. Beavis et al. also reported a role for anti-PD-1/CTLA-4 activated CD4+ Foxp3+ cells in enhancing IL-12 production by CD103+ DCs, which in turn promoted T cell-mediated anti-tumor immunity in mice (42). The persistence of intratumoral stimulatory DCs (CD103+ BDCA-3+) defined by gene expression profiles correlated with increased overall survival outcomes and was associated with higher TIL measurements in metastatic melanoma (43). Mediating the abundance of intratumoral stimulatory DCs was the presence of tumor-infiltrating natural killer cells and expression of FLT3L, together these components may assist in determining anti-PD-1 therapeutic response and identify therapeutic strategies to potentiate efficacy (43). More recently, a cluster of DCs named mregDCs (mature DCs enriched in immunomodulatory molecules) co-expressing immunoregulatory genes (Cd274, Pdcd1lg2, and Cd200) and maturation genes (Cd40, Ccr7, and Il12b) was found in single cell analysis of mouse and human non-small cell lung cancer (NSCLC) DC infiltrate (44). Of note, neutralizing IL-4 was shown to enhance mregDC IL-12 production, repressing lung adenocarcinoma in mice (44). With advances in high-throughput single-cell analysis to provide fine detail of immune infiltrate in tumors, it is likely to facilitate an expansion of our repertoire of novel targets that will assist to re-educate DCs and other myeloid cells specifically in the TME.

RE-EDUCATING SUPPRESSIVE AND UNCONVENTIONAL T CELLS IN THE TME

Regulatory T cells (Tregs) serve as a barrier to limit inflammation, however, their enrichment in the TME of established cancer correlates with poor prognosis and a dampened anti-tumor immune response (Figure 1). Clinical studies have resolved that a higher effector/Treg ratio is associated with favorable outcomes in multiple solid cancers (45, 46). In addition to Treg-induced suppression of effector T cells by manipulating their migration, activation, functionality and/or survival (47, 48), Tregs are able to form an immunosuppressive barrier capable of limiting the trafficking of activated antigen-specific CD8+ T cells into the TME (49). Importantly, Foxp3+ Tregs promote effector CD4+ and CD8+ TIL dysfunction, with improved cytokine-producing capacity upon Treg depletion and reinvigorated T cell responses to immune checkpoint blockade (50–52). However, systemic Treg depletion introduced transiently can still increase susceptibility of mice to autoimmunity (53), indicative that identifying an appropriate target to specifically remove intratumoral Foxp3+ Tregs will be advantageous for maintaining therapeutic safety.

Intratumoral Foxp3+ Tregs are highly suppressive, with an activated phenotype marked by the expression of several classes of immune receptors [ENTPD1 (CD39), CTLA-4,OX40, and GITR], and chemokine receptors (CCR4). Studies using preclinical mouse models showed that anti-CTLA-4 (clone 9H10, 9D9, and H11; antagonist), anti-OX40 (clone OX86; agonist) and anti-GITR (clone DTA-1; agonist) exhibited varying levels of intratumoral Treg depleting activity in vivo that was critical to their efficacy (54–59). Anti-CTLA-4 (clone 9D9, mouse IgG2a) and anti-OX40 were shown to specifically deplete intratumoral Tregs but not peripheral Tregs (56, 57). Tumor-infiltrating Treg depletion by anti-CTLA-4 enhanced anti-PD-1 sensitivity to the previously resistant AT3 mouse mammary carcinoma (36). In the clinic, mogamulizumab (an anti-human CCR4 antibody, engineered for ADCC activity) was developed to specifically deplete CCR4+ suppressive Tregs found in the TME (60), and is undergoing testing in combination with T cell checkpoint targets in Phase I/II clinical trials (NCT02301130, NCT02705105, NCT02476123, and NCT02946671). While it remains unclear whether combining anti-CCR4 and anti-PD-1 provides favorable survival benefits, an increase in the proportion of CD8+ T cells and a reduction in activated Foxp3hi Tregs was observed in TILs from patients, along with an acceptable safety profile [[61]; NCT02476123]. With advances in antibody engineering, we should expect refinement of antibodies for both existing and novel targets to modulate TME-specific Tregs to enhance anti-tumor immunity (51, 62, 63). Revisiting targeting CD25-expressing Tregs, Vargas et al. found that by altering the IgG backbone (from rat IgG1 to mouse IgG2a) greater specificity was afforded toward intratumoral Tregs but not peripheral Tregs (56, 57).
Given the critical role of Tregs in maintaining immune homeostasis, attenuating intratumoral Treg suppressive function may be a safer approach to remodel the TME while minimizing the risk of systemic autoimmunity. Studies from a series of experimental modeling showed that the disruption of Foxp3, the critical transcription factor to maintain Treg lineage, altered their suppressor function (65–67). This also resulted in the generation of pathogenic effector T cells (67, 68). However, disruption of intratumoral Treg suppressive function has been shown without the loss of its Foxp3\textsuperscript{+} Treg identity. Neuropilin-1 (NRP1) appears crucial to maintain intratumoral Treg stability without aberrant loss of Foxp3 identity, and anti-NRP1 displayed therapeutic efficacy in suppressing tumor growth (69). Notably, using a co-transfer model of NRPI-intact and NRPI-deficient Tregs, interferon (IFN)-\(\gamma\) produced by NRPI-deficient Tregs is capable of causing fragility to the suppressive capacity of NRPI-intact Tregs, resulting in improved host anti-tumor immunity (70). Similar to the role of NRPI to maintain Treg stability, the histone H3K27 methyltransferase enhancer of zeste homolog 2 (EZH2) has been recently shown to be critical for the maintenance of activated Foxp3\textsuperscript{+} Tregs (71). EZH2 inhibition destabilizes Foxp3 expression and inhibits tumor growth in vivo (72, 73). While targeting these pathways may be able to provide an opportunity to dismantle Treg suppression within the TME, these therapies still lack specificity to this cell type. Understanding the role of these molecules in multiple cell types and disease settings is likely to dictate their applicability for utility in cancer immunity.

Besides Tregs, unconventional T cells have also received considerable interest in tumor immunology for their immunoregulatory role. In contrast to CD8\textsuperscript{+} and CD4\textsuperscript{+} T cells that interact with MHC class I and II molecules, unconventional T cells such as natural killer T (NKT) cells interact with non-classical MHC CD1d molecules (74). \(\alpha\)-GalCer (a glycolipid molecule derived from a marine sponge extract) is a known ligand for NKT cells, and has been widely used to experimentally modulate NKT cells (75). \(\alpha\)-GalCer-activated NKT cells are capable of producing high levels of cytokines (including IFN-\(\gamma\) and IL-21), anti-tumor effector and cytotoxic molecules (perforin and granzymes), and elicit direct tumor lysing properties (76–78), which assists to alleviate immunosuppression and enhances DC maturation, leading to improved anti-tumor T cell immunity (79–81). Song et al. demonstrated that NKT cells specifically kill monocytes pulsed with neuroblastoma cell lysate and reduce tumor-infiltrating monocytes in a non-classical MHC-dependent manner (82), highlighting a role for NKT cells in shaping the immune infiltrate in the TME. Studies in mice reported superior anti-tumor activity when \(\alpha\)-GalCer therapy to drive NKT cell activity was combined with anti-PD-1 (83, 84). However, most clinical trials assessing the anti-tumor effect of \(\alpha\)-GalCer-related compounds have not yet yielded promising outcomes (74). Discoveries of novel NKT cell agonists (\(\beta\)-mannosylceramide) and improved \(\alpha\)-GalCer analogs (\(\alpha\)-C-GalCer) (74, 85), as well as greater understanding of tumors where this cell type is prominent may assist in harnessing the potential of NKT cells to improve T cell checkpoint therapy. Mucosal-associated invariant T (MAIT) cells are another class of unconventional T cell that have gained much attention, given their relative abundance in humans and their association to a number of inflammatory diseases (74). MAIT cells primarily recognize a number of microbial vitamin B metabolites (such as riboflavin metabolized to 5-OP-RU) (86–89) presented by the unconventional non-polymorphic MHC I-like molecule, MR1 (90). Additional MR1-independent IL-12/18-induced activation has been reported (91, 92). Upon activation, MAIT cells are capable of producing cytokines ([IL-17, IL-2, IFN-\(\gamma\), and tumor necrosis factor (TNF)], proliferate and gain cytotoxic function (93–95). In the absence of defined tumor antigens binding to tumor-derived MR1, it is reasonable to speculate that MAIT cells may be regulated by microbial antigens and may be more frequent in tumors with a microbial presence. Circulating levels of MAIT cells were reduced in patients with mucosal-originated cancers (gastric, colon, and lung), but appeared normal in patients with breast, liver, or thyroid cancer (96). In colon cancer patients, MAIT cells were shown to be preferentially enriched in the TME in comparison to unaffected tissue (96–99). Poor survival prognosis has been associated to increased levels of tumor-infiltrating MAIT cells in colon cancer patients (98). In contrast, MAIT cells did not show a correlation to patient survival in esophageal adenocarcinoma (100). In concordance with the activation of MAIT cells (TCR-MR1 or IL-12/18 cytokine), they likely elicit direct (MAIT cell to tumor cell) and indirect (MAIT cell to non-MAIT cell or IL-12/18 cytokine competition) effects, regulating host anti-tumor immunity in a TME-specific manner (74, 101). Yan et al. recently reported MR1-deficient mice (which lack MAIT cells) showed improved anti-tumor immunity when assessed using models of experimental lung metastasis, subcutaneous tumor growth, and \textit{de novo} carcinogenesis (102). In light of these findings, a further assessment of MAIT cells in the context setting and their relationship to prognosis and therapeutic outcome should be determined. In addition, given a great interest in microbial modification of the TME (103–105) determining whether microbes can be used to initiate metabolic functions that promote anti-tumor immunity is also of interest.

**LIMITING IMMUNOSUPPRESSIVE FACTORS IN THE TME**

As well as initiation of immunosuppression by immune cell subsets, the tumor itself produces a range of molecules to enable tumor progression and facilitate immune escape (Figure 1). Many of these are soluble factors that prevent overzealous inflammation during tissue damage and infection, however also mediate tumor immune evasion. Transforming growth factor (TGF)\(\beta\) plays an essential role in mediating immune homeostasis, however, in the context of tumor, TGF\(\beta\) has been shown to both directly promote tumor progression and initiate a broad range of immune responses. These include enhancing suppressive myeloid cell infiltrate (106, 107), disabling NK cell function,
and promoting transition to group 1 innate lymphoid cells in the TME (108), as well as altering the functionality of effector T cell populations while promoting Treg immune suppression (109–111). SMAD-3, which acts downstream of TGFβ1 signaling, directly induces PD-1 expression in adoptively transferred tumor antigen-specific CD8+ T cells isolated from the TME (112). This suggests that PD-1-upregulation that facilitates tumor immune escape may in part be dependent on TGFβ. In addition, TGFβ is associated with excluding CD8+ T cell entry into the tumor core, which is known to diminish immunotherapy efficacy (113). Correspondingly, TGFβ1 gene expression is significantly higher in patients that show stable or progressive disease, compared to those with complete or partial responses (113). Targeting TGFβ and therapies directed toward PD-1/PD-L1 or CTLA-4 amplifies tumor control by enabling a robust T cell response with improved CD4+ and CD8+ T cell activation and CD8+ T cell cytokine and cell killing capacity (113–116). By inhibiting TGFβ in combination with PD-1/PD-L1 blockade, CD8+ T cells also display enhanced capacity to infiltrate the tumor periphery and core, promoting T cell inflammation, and resolving T cell exclusion (113, 117). This highlights that targeting TGFβ may be most effective in tumor types in which TGFβ signaling mediates immune exclusion from the TME.

Impeding the clinical utility of pan-TGFβ inhibitors (blocking isoforms TGFβ1,−2, and−3) is the potential for significant toxicity, particularly pertaining to cardiac function. Development of galunisertib (LY2157299), a TGFβRI inhibitor, has shown promise for both its anti-tumor activity and ability to modulate the TME to provide improved anti-tumor control to immunotherapies (118). However, due to toxicity concerns, intermittent administration of galunisertib has been performed in clinical trials [119 NCT01246986]. Whether intermittent drug exposure provides selective pressure for tumor escape is unclear. As TGFβ1 appears to be the predominantly enriched in human cancers, targeting this isoform specifically may prove advantageous. Development of TGFβ1-specific inhibitors that promote synergistic anti-tumor immune responses when combined with anti-PD-1, but lack cardiovascular pathologies have been identified and may lead to greater clinical utility (120). Downstream targets of tumor-derived TGFβ activation may also be more desirable and in some cases are already being assessed for therapeutic potential alongside immune checkpoint inhibitors and other immunomodulatory compounds in the clinic.

Angiogenesis in the TME is an important component to enable nutrient accessibility and maintain tumor growth, this is driven in part by TGFβ induction of vascular endothelial growth factor (VEGF). While VEGF inhibitors have been approved for a number of indications in both oncology and vascular-related diseases, in the cancer setting interest in both anti-angiogenic and immunomodulatory properties for this target are increasing. Notably, VEGF-A promotes inhibitory checkpoint expression and transcriptional reprogramming relating to exhaustion in CD8+ T cells (121, 122). TOX, the transcription factor that mediates CD8+ T cell exhaustion, was shown to be tightly regulated by VEGF-A (122). In addition, both VEGF-A and TOX expression levels were significantly reduced in MSI-h colon cancer patients compared to patients with microsatellite stability (122). MSI-h patients have better survival outcomes in response to cancer immunotherapies, which is predominantly attributed to higher tumor mutational burden (123, 124), but may also be in part be due to reduced angiogenic factors and relieved T cell exhaustion. By combining VEGF-targeted therapies and anti-PD-1, improved anti-tumor immune response was achieved (121, 122). However, TGFβ and VEGF are not completely redundant, and co-targeting these molecules together either therapeutically or through tumor-specific genetic ablation provides additional therapeutic benefit to overcome immune tolerance in the TME (125). As clinical cohorts involving combination VEGF/TGFβ and immune checkpoint blockade treatment mature, determining which patients respond to this therapy, but also which patients are refractory and the mechanism that initiates tumor escape is of importance.

Generation of immunosuppressive adenosine limits anti-tumor immunity (126). Both CD39, which catabolizes ATP to AMP, and CD73, the enzyme that generates adenosine from AMP, and CD73, are expressed by and relate to poor prognosis in a number of cancer types (127–130). Regulation of tumor-derived CD73 remains complex with multiple mediators identified, including TGFβ (131, 132). Additional evidence that CD73 expression is driven by adenosine-sensing through host-A2A adenosine receptor (A2AR) expression (133, 134), TNF (135), and hypoxia within the TME (136, 137). In melanoma, CD73 levels have been linked to low MITF expression and highly invasive tumors (135). CD73 expression appears to increase with adaptive resistance in anti-PD-1-treated melanoma patients as well as MART-1 adoptive T cell therapy (135), suggesting that tumor expression may facilitate therapeutic resistance in response to active anti-tumor immunity. In melanoma patients with innate therapeutic resistance, CD73 is not present or induced with exposure to anti-PD-1 treatment (135), likely due to a lack of inflammatory stimuli in the TME. Therapies targeting the adenosinergic pathway have been shown preclinically to potentiate the response of chemotherapies (127), immune checkpoint inhibitors (138, 139), chimeric antigen receptor T cells (140) and oncogenic BRAF inhibitors (141). This can also be through indirectly targeting the adenosine pathway, with both systemic oxygenation which relieves hypoxia-driven adenosine production, and blockade of an alternate mechanism of adenosine-production by inhibiting CD38, with both shown to potentiate the therapeutic efficacy of immune checkpoint blockade (137, 142, 143). Similarly, targeting upstream CD39 has been shown preclinically to promote therapeutic activity of immune checkpoint inhibitors (144), chemotherapies (145), and even can potentiate CD73 blockade in suboptimal concentrations (146). This highlights the complex regulatory network and the multi-faceted combination strategies involving adenosine-related molecules that may add benefit to patient care.

Targeting adenosine production and signaling have both moved forward to early phase clinical trials with promising results (NCT02403193, NCT02503774, NCT03454451). Notably, citoforadenant (an A2AR inhibitor) in combination with atezolizumab (anti-PD-L1) initiated therapeutic response in
both patients naïve to immunotherapies and those refractory to prior immunotherapy exposure, highlighting the potential for this combination to reinvigorate anti-tumor immunity (147). Analysis of tumor biopsies from renal cell carcinoma (RCC) preceding therapeutic intervention revealed an adenosine signature that may predict patients who will benefit from adenosine-related therapies (147). The adenosine signature was consistent with myeloid inflammation and reduced angiogenesis, both of which have been defined as poor prognostically for atezolizumab and sunitinib (tyrosine kinase inhibitor) treatment. This identifies a patient group for which adenosine may be most applicable, that inadvertently are less responsive to currently clinically approved therapies for RCC. In addition, an extended disease control rate in response to ctitfordenat, with or without atezolizumab, was linked to improved CD8+ T cell infiltration (147). Adenosine has previously been shown to limit the proliferation and maturation of lymphocytic immune cell subsets (126, 134), and increased immune infiltrate in to the tumor core has been observed in response to co-targeting CD73 and A2AR in preclinical models (133). Understanding the regulation of the adenosinergic pathway in particular tumor types and in response to cancer therapies, including immunotherapy, may identify patient populations where adenosine-related therapies may be implemented with greatest success.

With increasing examination of the TME it is clear that a number of therapeutic regimens may be successfully repurposed in the treatment of cancer. For instance, targeting adenosine has been utilized previously in the setting of neurodegeneration, but has increasingly shown merit for initiating anti-tumor immunity. Additionally, aspirin may provide a combinatorial approach to overcome therapeutic resistance to immune checkpoint inhibitors. Increasing evidence demonstrates that cyclooxygenase (COX)-driven production of prostaglandins mediates anti-PD-1 resistance and limits the proinflammatory tumor milieu (148). COX enzymatic activity is disrupted by high-dose aspirin, which valuably may be repurposed to the cancer setting alongside immunotherapies to promote anti-tumor immunity. Regular aspirin users with colorectal cancer patients displaying low tumor PD-L1 expression are also afforded significantly improved survival outcomes (149). This survival advantage was not identified in PD-L1 high tumors, suggesting that engagement of the PD-1/PD-L1 axis in the TME may abrogate aspirin-mediated anti-tumor benefit and the potential utility of combination treatment. Genetic ablation of prostaglandin-endoperoxide synthase 2 (PTSG2), which encodes COX-2, has been shown to promote CD8+ T cells and decrease the frequency of Tregs within the TME (150), both of which are predictive markers of good prognosis. Induction of COX-2 may be in part regulated by TGFβ, highlighting the complex nature of direct and indirect regulatory pathways that the tumor elicits to subdue the anti-tumor immune response. Clinical trials to develop an understanding of prostaglandin/COX-2 inhibition and immune checkpoint blockade therapeutic responses are underway in multiple tumor types ([151] NCT03396952, NCT03638297, NCT03864575, NCT03926338).

IMPLEMENTING COMBINATION THERAPEUTIC REGIMENS

While preclinical studies have identified a number of clinically relevant therapeutic strategies to reinvigorate the immune response against cancer, their successful clinical utility has been difficult to implement (Figure 2). Combining indoleamine 2,3-dioxygenase (IDO) inhibition, an enzyme upregulated in human cancers that initiates the breakdown of tryptophan leading to multi-faceted immunosuppression within the TME (152), alongside immune checkpoint inhibitors showed promise for enhancing anti-tumor immunity in mice (153, 154). However, in a phase 3 clinical trial assessing the survival benefit for stage III/IV unresectable melanoma patients treated with epcadostat (selective IDO1 inhibitor) and pembrolizumab (anti-PD-1), this combination failed to provide additive therapeutic potential compared to pembrolizumab alone (155). Improved understanding of the TME is necessary to assist rational selection of immunotherapies required for optimal treatment outcomes. Of course, this remains a challenge even for clinically approved agents, where aside from tumor PD-L1 expression and genetic stability of the tumor, no biomarkers for efficacy or toxicity of immune checkpoint inhibitors are approved for clinical use. Significant investment to establish biomarkers to denote responders and non-responders should be performed in early phase clinical trials to identify subgroups for which combination therapies may show greatest activity, an important first-step to facilitate response, mitigate toxicity, and minimize unnecessary cost.

In the same vein, examining optimal timing for immunotherapeutic combinations is often not well-defined. In most cases, therapeutic benefit for novel clinical agents are tested either alone or alongside concurrent anti-PD-1/PD-L1 treatment, often in cancer patients refractory to previous immune checkpoint inhibitor exposure. Preclinical evidence suggests synchronous administration of multiple immunotherapies can in some circumstances be detrimental. Two independent studies identified that concurrent administration of anti-OX40 to anti-PD-1 therapy either with or without a tumor vaccine diminished the anti-tumor immune response compared to addition of anti-OX40 alone in preclinical mouse models (156, 157). Notably, staggering the timing of these therapies where anti-OX40 preceded anti-PD-1 treatment facilitated greatest tumor control (156). Using a preclinical PDAC model, the use of gemcitabine and nab-paclitaxel, a standard chemotherapy combination for PDAC, impaired the efficacy of anti-CD40, anti-PD-1, and anti-CTLA-4 (34). Additionally, transient treatments preceding immune checkpoint inhibition can also significantly re-educate the immune response to promote anti-tumor immunity. In an anti-PD-1-resistant mouse model, a single-dose of agonistic anti-CD40 sensitized the TME to anti-PD-1 treatment in a synergistic manner (36). Strongly activating or agonistic therapies may provide greatest benefit as sensitizing agents to remodel the TME and promote entry of anti-tumor immune cells that are then targetable by immune checkpoint blockade. Alternating timing of treatments or reducing the therapeutic window for
largely inflammatory combinations may also assist to potentiate therapeutic response and minimize immunotherapy-induced immune-related adverse events (irAEs).

**CHALLENGES FOR RE-EDUCATING THE TME**

With the advent of high-throughput screening to delineate critical components that prevent immune infiltrate or disable active anti-tumor immunity, a growing understanding of rational targets to re-ignite a therapeutic response is becoming increasingly available (158–161). This aims to equip patients who develop adaptive or acquired resistance with greater tools to re-engage the immune response against cancer and for patients with innate resistance to enable visibility of tumors (162, 163). New subgroups of cancer patients that present distinct challenges to the efficacy of immunotherapies are emerging. Of growing interest, is the relationship between metastatic site and therapeutic outcome, in which liver metastasis appears to be a major obstacle even for combination anti-PD-1 and anti-CTLA-4 treatment (164, 165). Most prominently, melanoma patients bearing liver metastasis have reduced CTLA-4 and PD-1 co-expression in CD8+ T cells (164), which has been shown to stratify therapeutic response to immune checkpoint inhibitor treatment (166). Efforts to provide mechanistic insight...
as to whether therapeutic resistance is due to myeloid cell dysfunction, Treg suppression, and immunosuppressive factors accumulating in the TME are essential, highlighting the need for tailored immunotherapies.

As the number and type of combination immunotherapies expands, the risk for increasing irAEs may also become more prevalent. Combination nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) clearly exhibits greater levels of severe grade 3-4 immunotoxicities than either therapy alone (3, 167). Surprising levels of irAEs have been observed with other rational combinations. For instance, targeted therapies (such as BRAF inhibitors and MEK inhibitors) have been shown to potentiate immune checkpoint inhibitor activity in preclinical models (168), but when used together in melanoma patients severe irAEs were observed forcing closure of the study (169, 170). This highlights a need for improved preclinical models that emulate clinical conditions and allow for simultaneous assessment of tumor control and development of irAEs (171). Developing tumor models in autoimmune-prone mice or lowering the threshold for self-tolerance in mice with available syngeneic tumors that are resistant to autoimmune responses may facilitate improved therapeutic modeling (53, 171, 172). With the expanding use of cancer immunotherapies in more diverse populations of cancer patients, including those with pre-existing autoimmune diseases or previous immunotherapy-induced irAEs (173), or under persistent immunosuppression due to chronic viral infections (174) and allogeneic transplantation (175), developing preclinical models that incorporate multiple elements relating to tumor origin, patient history, and environment that assist in providing a more informed understanding of the clinical impact of therapeutic combinations will be essential.

As the number of immunotherapeutic targets expands, initiating smarter multi-modal strategies, to provide greater efficacy with lower toxicity will be appealing. Advancement in engineering therapies to have delayed release or greater tissue and cellular specificity have great promise. As mentioned, depletion of intratumoral Tregs without impacting peripheral Tregs would be advantageous for inducing TME-specific modulation of the CD8+ T cells and reduced Tregs specifically within the TME, while avoiding toxicity induced by systemic depletion. Notably, the development of a dual variable domain anti-CTLA-4 antibody, which exhibits an outer tumor antigen-binding site that hides the CTLA-4 binding region of the antibody until reaching the TME has been shown to reduce immunotherapy-induced toxicity without impeding anti-tumor immunity (176). Similarly, bispecific or trispecific antibodies that target multiple markers upregulated in the TME on both immune cell subsets and the tumor may also lead to greater efficacy (177, 178). One such example, is the bispecific antibody combination targeting OX40 and CTLA-4, which significantly enhanced CD8+ T cells and reduced Tregs specifically within the TME, leading to better tumor control than either therapy alone (178). In addition to modifying the target antigen, antibodies may also be conjugated to biomaterials or nanoparticles, to ensure sustained, local release (179). Refinement made to antibodies by factoring TME properties, such as pH activation and PD-1 glycosylation (180–182), should also significantly improve the specificity and potency of immunotherapies and limit unwanted toxicity.

**FUTURE DIRECTIONS**

While determining the optimal immunotherapy for an individual TME remains a challenge, encouraging is the range of available strategies to re-educate the immune response against tumor. Refinement of therapeutic targets against cellular and immunomodulatory molecules within the TME are increasing, and their promise for clinical utility is growing. Importantly, greater effort in defining the therapeutic setting where each may be applicable will be essential for clinical success. Since anti-PD-1/PD-L1 has shown value in multiple modalities, examining tumor types where anti-PD-1 activity is limited may yield greatest therapeutic breakthroughs in identifying strategies to remodel inert immune circumstances in the tumor. In deciding on the use of these therapies, a cost-benefit analysis relating to the purported immunotoxicity and likelihood for the immunotherapy strategy to enhance anti-tumor immunity is necessary. This emphasizes a need for rational and selective combination immunotherapies to be utilized within a defined TME in order to re-educate the anti-tumor immune response.

**AUTHOR CONTRIBUTIONS**

SN and AY contributed equally to the writing and revision of the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

SN was supported by an NHMRC C.J. Martin Fellowship (GNT1111469) and the Mark Foundation for Cancer Research Momentum Fellowship. AY was supported by a NHMRC C.J. Martin Fellowship (GNT1143981). Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number K99CA246061 (AY). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**REFERENCES**

1. Khalil DN, Smith El, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. (2016) 13:394. doi: 10.1038/nrclinonc.2016.65
2. Hammers HJ, Pлимack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the checkmate 016 study. J Clin Oncol. (2017) 35:3851–8. doi: 10.1200/JCO.2016.72.1985
3. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. (2017) 377:1345–56. doi: 10.1056/NEJMoa1709684
4. Rizvi NA, Hellmann MD, Snyder A, Kivistö P, Makarov V, Havel JJ, et al. Cancer immunology. mutational landscape determines sensitivity to
1. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, et al. Tumor mutational burden and non-redundant immune mechanisms in cancer. *Nature.* (2015) 520:373–7. doi: 10.1038/nature14292

2. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and immunotherapy that engages innate and adaptive immune responses. *Nature Med.* (2017) 23:1014–20. doi: 10.1038/nm.4353

3. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. *Cell.* (2017) 170:1120–33. doi: 10.1016/j.cell.2017.07.024

4. Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. *Cancer Res.* (2013) 73:1128–41. doi: 10.1158/0008-5472.CAN-12-2731

5. Wuxu, Singh R, Hsu DK, Zhou Y, Yu S, Han D, et al. A small molecule CCR2 antagonist decreases tumor macrophages and synergizes with anti-PD-1 in a murine model of cutaneous T-cell lymphoma (CTCL). *J Invest Dermatol.* (2020) 140:1390–400.e4. doi: 10.1016/j.jid.2019.11.018

6. Grossman JG, Nywening TM, Belt BA, Panni RZ, Krasnick BA, DeNardo DG, et al. Recruitment of CCR2(+) tumor associated macrophage to sites of liver metastasis confers a poorer prognosis in human colorectal cancer. *Oncometabolism.* (2018) 7:e1470729. doi: 10.1016/j.2018.1470729

7. House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. *Clin Cancer Res.* (2020) 26:487–504. doi: 10.1158/1078-0432.CCR-19-1868

8. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. *Cancer Res.* (2007) 67:9518–27. doi: 10.1158/0008-5472.CAN-07-0175

9. Aiello NM, Bajor DL, Norgard RJ, Sahmoud A, Bhagwat N, Pham MN, et al. Metastatic progression is associated with dynamic changes in the local microenvironment. *Nat Commun.* (2016) 7:12819. doi: 10.1038/ncomms12819

10. Vonderheide RH. The immune revolution: a case for priming, not checkpoint. *Cancer Cell.* (2018) 33:563–9. doi: 10.1016/j.ccell.2018.03.008

11. Morrison AH, Diamond MS, Hay CA, Byrne KT, Vonderheide RH. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity. *Proc Natl Acad Sci USA.* (2020) 117:8022–31. doi: 10.1073/pnas.1918971117

12. Luheishi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, et al. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. *OncoTarget.* (2016) 7:18508–20. doi: 10.18632/oncotarget.7610

13. Ngio SF, Young A, Blake SJ, Hill GR, Yagita H, Teng MW, et al. Agonistic CD40 mAb-driven IL12 reverses resistance to anti-PD1 in a T-cell-rich tumor. *Cancer Res.* (2016) 76:6266–77. doi: 10.1158/0008-5472.CAN-16-2141

14. Salmon H, Ioigaya J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. *Immunity.* (2016) 44:924–38. doi: 10.1016/j.immuni.2016.03.012

15. Hildner K, Edelson BT, Purtha WE, Diamond M, Matushita H, Kohyama M, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. *Science.* (2008) 322:1097–100. doi: 10.1126/science.1164206

16. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and immunotherapy that engages innate and adaptive immune responses. *Nature Med.* (2017) 23:1014–20. doi: 10.1038/nm.4353

17. Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells. *Oncoimmunology.* (2013) 2:e26968. doi: 10.4161/onci.26968

18. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells. *Oncoimmunology.* (2013) 2:e26968. doi: 10.4161/onci.26968

19. Zuo C, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells. *Oncoimmunology.* (2013) 2:e26968. doi: 10.4161/onci.26968

20. Ngiow SF, Meeth KM, Stannard K, Barkauskas DS, Bollag G, Rosenberg M, et al. Inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF(V600E) melanoma. *Oncoimmunology.* (2016) 5:e1089381. doi: 10.2147/1089381

21. DeNardo DG, Brennan DJ, Resheph E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. *Cancer Discov.* (2011) 1:54–67. doi: 10.1158/2159-8274.CD-10-0028

22. Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1R receptor blockade by inducing PMN-MDSC infiltration of tumors. *Cancer Cell.* (2017) 32:654–68.e5. doi: 10.1016/j.ccell.2017.10.005

23. Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. Fc gammaRs

24. Fine AJ, Binnwieser B, Nelson AE, Pollack JL, Erle DJ, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. *Cancer Cell.* (2014) 26:638–52. doi: 10.1016/j.ccell.2014.09.007
40. Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, et al. Macrophage IL-10 blocks CD8+ T-cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. *Cancer Cell.* (2014) 26:623–37. doi: 10.1016/j.cccel.2014.09.006

41. Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, et al. Critical role for CD103+(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. *Cancer Cell.* (2016) 30:324–36. doi: 10.1016/j.cccel.2016.06.003

42. Beavis PA, Henderson MA, Giuffrida L, Davenport AJ, Petley EV, House JG, et al. Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4+(+)/FoxP3(+) cell-mediated modulation of CD103(+) dendritic cells. *Cancer Immunol Res.* (2018) 6:1069–81. doi: 10.1158/2326-6066.CIR-18-0291

43. Barry KC, Hsu J, Broz ML, Cueto FJ, Binnewies M, Combes AJ, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. (2018) 24:1178–91. doi: 10.1038/s41591-018-0085-8

44. Maier B, Chen ST, Tung N, Chang C, LeBerichel J, Chudnovsky A, et al. A conserved dendritic-cell regulatory program limits anti-tumor immunity. *Nature.* (2020) 508:257–62. doi: 10.1038/s41586-020-2134-y

45. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumors: impact on clinical outcome. *Nat Rev Cancer.* (2012) 12:298–306. doi: 10.1038/nrc3245

46. Shen B, Liu Y, Jiang SJ, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. *Sci Rep.* (2015) 5:15179. doi: 10.1038/srep15179

47. Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. *Cell Res.* (2017) 27:109–18. doi: 10.1038/cr.2016.151

48. Binnewies M, Miu AMJ, Pollock JL, Combes AJ, Hardison EA, Barry KC, et al. Unleashing type-2 dendritic cells to drive protective anti-tumor CD4(+) T cell immunity. *Cell.* (2019) 177:556–71.e16. doi: 10.1016/j.cell.2019.02.005

49. Qi S, Li H, Lu L, Qi Z, Liu L, Chen L, et al. Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy. *Elife.* (2016) 5:e4756. doi: 10.7554/eLife.4756

50. Taylor NA, Vick SC, Iglesia MD, Brickey WJ, Midkiff BR, McKinnon KP, et al. Assessing immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer. *Cancer Immunol Res.* (2014) 2:1905–18. doi: 10.1158/2326-6066.ICR-13-1003

51. Bournazos S, Wang TT, Dahan R, Mazzara J, Ravech JV. Signaling by antibodies: recent progress. *Annu Rev Immunol.* (2017) 35:285–311. doi: 10.1146/annurev-immunol-051116-052433

52. Arce Vargas F, Furness AJ, Solomon I, Joshi K, Mekkaoui L, Lesko MH, et al. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. *Immunity.* (2017) 46:577–86. doi: 10.1016/j.immuni.2017.03.013

53. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. *Annu Rev Immunol.* (2012) 30:531–64. doi: 10.1146/annurev.immunol.25.022106.141623

54. van Goor F, Nguyen MLT, Mumbach MR, Satpathy AT, Rosenthal WL, Giacometti S, et al. A mutation in the transcription factor Foxp3 drives T helper 2 effector function in regulatory T cells. *Immunity.* (2019) 50:362–77.e6. doi: 10.1016/j.immuni.2018.12.016

55. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. *Immunity.* (2010) 236:219–42. doi: 10.1111/j.1600-065X.2010.00923.x

56. Wan YJ, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. *Nature.* (2007) 445:766–70. doi: 10.1038/nature05479

57. Delgoffe GM, Woo SR, Turnis ME, Gravano DM, Guy C, Overacre AE, et al. Stability and function of regulatory T cells is maintained by a neurophilin-1-sемaphorin-4а axis. *Nature.* (2013) 501:252–6. doi: 10.1038/nature12428

58. Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, et al. Interferon-gamma drives Treg fragility to promote anti-tumor immunity. *Cell.* (2017) 169:1130–41.e11. doi: 10.1016/j.cell.2017.05.005

59. DuPage M, Chopra G, Quirós J, Rosenthal WL, Morar MM, Holohan D, et al. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. *Immunity.* (2015) 42:227–38. doi: 10.1016/j.immuni.2015.01.007

60. Wang D, Quirós J, Mahuron K, Pai CC, Ranzani V, Young A, et al. Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity. *Cell Rep.* (2018) 23:3262–74. doi: 10.1016/j.celrep.2018.05.050

61. Goswami S, Apostolou I, Zhang X, Skepner J, Anandhan S, Zhang X, et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. *J Clin Invest.* (2018) 128:3813–8. doi: 10.1172/JCI99760

62. Godfrey DI, Le Nours J, Andrews DM, Uldrich AP, Rossjohn J. The role of NKT cell cytokines in tumor immunity. *Trends Immunol.* (2007) 28:39–45. doi: 10.1016/j.cell.2018.02.010

63. Josifovitch Y, Mandelboim O, Pellegrino M, Kipnis J, van Vliet AJ, federal government. *Science.* (1997) 278:1626–9. doi: 10.1126/science.278.5343.1626

64. Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, et al. Human NKT cells mediate antitumor cytoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. *J Immunol.* (2001) 167:3114–22. doi: 10.4049/jimmunol.167.6.3114

65. Coquet JM, Chakravarti S, Kypharisoudis K, McNab FW, Pitt LA, McKenzie BS, et al. Dense cytokine production by NK cell subsets and identification of an IL-17-producing CD4+CD11c+ NK cell population. *Proc Natl Acad Sci USA.* (2008) 105:11287–92. doi: 10.1073/pnas.0806131105
Won EJ, Ju JK, Cho YN, Jin HM, Park KJ, Kim TJ, et al. Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer. Oncotarget. (2016) 7:76274–90. doi: 10.18632/oncotarget.11187

79. Sandstrom P, Ahlmann F, Akeus P, Sundquist M, Alsen S, Yrlid U, et al. Human mucosa-associated invariant T cells accumulate in colon adenocarcinomas but produce reduced amounts of IFN-gamma. J Immunol. (2015) 195:3472–81. doi: 10.4049/jimmunol.1500258

80. Zabjik L, Attencourt C, Guignant C, Chateilain D, Marcelo P, Marello JP, et al. Increased tumor infiltration by mucosal-associated invariant T cells correlates with poor survival in colorectal cancer patients. Cancer Immunol Immunother. (2015) 64:1601–8. doi: 10.1007/s00262-015-1764-7

81. Ling L, Lin Y, Zheng W, Hong S, Tang X, Zhao P, et al. Circulating and tumor-infiltrating mucosal associated invariant T (MAIT) cells in colorectal cancer patients. Sci Rep. (2016) 6:20358. doi: 10.1038/srep20358

82. Melo AM, O’Brien AM, Phelan JJ, Kennedy SA, Wood NAW, Veerapen N, et al. Mucosal-associated invariant T cells display diminished effector capacity in oesophageal adenocarcinoma. Front Immunol. (2019) 10:1580. doi: 10.3389/fimmu.2019.01580

83. Godfrey DI, Koay HF, McLuskey J, Gherardin NA. The biology and functional importance of MAIT cells. Nat Immunol. (2019) 20:1110–28. doi: 10.1038/s41590-019-0444-8

84. Yan J, Allen S, McDonald E, Das I, Mak JYK, Liu L, et al. MAIT cells promote tumor initiation, growth, and metastases via tumor MR1. Cancer Discov. (2020) 10:124–41. doi: 10.1158/2159-8290.CD-19-0569

85. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. (2018) 359:97–103. doi: 10.1126/science.aac236

86. Vetizou M, Pitt JM, Dailiere R, Lepage Y, Veronesi E, et al. Anticancer immunity by CTLA-4 blockade relies on the gut microbiota. Science. (2015) 350:1079–84. doi: 10.1126/science.aac329

87. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. (2015) 350:1084–9. doi: 10.1126/science.aac325

88. Pang Y, Gara SK, Achbyut BR, Li Z, Yan HH, Day CP, et al. TGF-β signaling in myeloid cells is required for tumor metastasis. Cancer Discov. (2013) 3:936–51. doi: 10.1158/2159-8290.CD-12-0527

89. Novitsky SV, Pickup MW, Chytal A, Polouskchina D, Owens P, Moses HL. Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties. J Leukoc Biol. (2012) 92:641–51. doi: 10.1189/jlb.1211163

90. Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngio SF, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol. (2017) 18:1004–15. doi: 10.1038/ni.3800

91. Thomas DA, Massague J. TGF-β signaling is the main regulator of SMAD3 activity in cancer. Cancer Discov. (2018) 8:369–80. doi: 10.1158/2159-8290.CD-17-0684

92. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc Natl Acad Sci USA. (2005) 102:4192–6. doi: 10.1073/pnas.0408179102

93. Budhu S, Schaefer DA, Li Y, Toledo-Crow R, Panageas K, Yang X, et al. Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Sci Signal. (2017) 10:ealak9702. doi: 10.1126/scisignal.aalak9702

94. Park BV, Freeman ZT, Ghazemzadeh A, Chatterton MA, Rutembwerwa A, Steigner J, et al. TGF-β1-mediated SMAD3 enhances PD-1 expression on antigen-specific T cells in cancer. Cancer Discov. (2016) 6:1366–81. doi: 10.1158/2159-8290.CD-15-1347

95. Marithasan S, Turley SJ, Dickes D, Castiglioni A, Yuen K, Wang Y, et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exhaustion of T cells. Nature. (2018) 554:544–8. doi: 10.1038/nature25501

96. Sow HS, Ren J, Camps M, Osendorf F, Ten Dijke P, Combined inhibition of TGF-β signaling and the PD-L1 immune checkpoint is differentially effective in tumor models. Cells. (2019) 8:320. doi: 10.3390/cells08040320
Nagata Y, Ezoe S, Fujita J, Okuzakis D, Motooka D, Ishiba shi T, et al. Targeting cancer-derived TGFβ enhances the efficacy of cancer immunotherapy. Nat Commun. (2018) 9:741. doi: 10.1038/s41467-017-02696-6

Dodagatta-Marri E, Meyer DS, Reeves MQ, Paniagua R, To MD, Binnewies M, et al. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by alpha-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. J Immunother Cancer. (2019) 7:62. doi: 10.1186/s41447-018-0493-9

Holmgard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY, Xu X, et al. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J Immunother Cancer. (2018) 6:47. doi: 10.1186/s41445-018-0356-4

Herberts S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, Estrem JM, et al. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-β signaling pathway. Drug Des Devel Ther. (2015) 9:4799–9. doi: 10.2147/DDDT.S86621

Martin C, Datta A, Littlefield C, Kalra A, Chapron C, Wawersik S, et al. Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. Sci Transl Med. (2020) 12eaay8456. doi: 10.1126/scitranslmed.aaay8456

Voron T, Calossi O, Marcheau E, Pernot S, Nizard M, Pointet AL, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med. (2015) 212:139–48. doi: 10.1084/jem.20140559

Kim CG, Jang M, Kim Y, Leem G, Kim KH, Lee H, et al. VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. Sci Immunol. (2019) 4eaay0555. doi: 10.1126/sciimmunol.aay0555

Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. (2016) 22:813–20. doi: 10.1158/1078-0432.CCR-15-1678

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. CD8+ T cell blockade augments PD-1 inhibition to promote T-cell-mediated anti-tumor immunity leading to durable, complete responses as monotherapy and in combination with checkpoint blockade. J Immunother Cancer. (2018) 6:47. doi: 10.1186/s41445-018-0356-4

Cai XY, Wang XF, Li J, Dong JN, Liu JQ, Li NP, et al. High expression of CD39 in gastric cancer reduces patient outcome following radical resection. Oncol Lett. (2012) 4:2080–6. doi: 10.3892/ol.2012.1589

Chen S, Fan J, Zhang M, Qin L, Domínguez D, Long A, et al. CD37 expression on effector T cells sustained by TGFβ facilitates tumor resistance to anti-4-1BB/CD137 therapy. Nat Commun. (2019) 10:130. doi: 10.1038/s41467-018-0128-3

Rhyoth SV, Pickup MW, Chytl A, Gorska AE, Zhang Q, Owens P, et al. Role of TGFβ signaling in generation of CD39+CD47+ myeloid cells in tumors. J Immunol. (2014) 193:3155–64. doi: 10.4049/jimmunol.1400578

Young A, Ngio SF, Barksaaks DS, Sult E, Hay C, Blake SJ, et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell. (2016) 30:391–403. doi: 10.1016/j.ccell.2016.06.025

Young A, Ngio SF, Gao Y, Patch AM, Barksaaks DS, Messeaudenne M, et al. A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Res. (2018) 78:1003–16. doi: 10.1158/0008-5472.CAN-17-2826

Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, et al. MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy. Cancer Res. (2017) 77:4697–709. doi: 10.1158/0008-5472.CAN-17-0395

Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. (1997) 57:2602–5.

Hatfield SM, Kjaergaard J, Lukashev D, Belikoff B, Schreiber TH, Sethumadhavan S, et al. Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1alpha-dependent and extracellular adenosine-mediated tumor protection. J Mol Med. (2014) 92:1283–92. doi: 10.1007/s00109-014-1189-3

Iannone R, Miele L, Maiolino P, Pinto A, Morello S. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am J Cancer Res. (2014) 4:172–81.

Mittal D, Young A, Stannard K, Yong M, Teng MW, Allard B, et al. Antitumor metastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. (2014) 74:3652–8. doi: 10.1158/0008-5472.CAN-14-0957

Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, et al. Targeting the adenosine A2 receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. (2017) 127:929–41. doi: 10.1172/JCI89455

Young A, Ngio SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, et al. Targeting adenosine in BRF-mutant melanoma reduces tumor growth and metastasis. Cancer Res. (2017) 77:4684–96. doi: 10.1158/0008-5472.CAN-17-0393

Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov. (2018) 8:1156–75. doi: 10.1158/2159-8290.CD-17-1033

Hatfield SM, Kjaergaard J, Lukashev D, Schreiber TH, Belikoff B, Abbott R, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med. (2015) 7:277ra30. doi: 10.1126/scitranslmed.aad1260

Li XY, Moesta AK, Xiao C, Nakamura K, Casey M, Zhang H, et al. Targeting CD39 in cancer reveals an extracellular ATP-driven and inflammasome-driven tumor immunity. Cancer Discov. (2019) 9:1754–73. doi: 10.1158/2159-8290.CD-19-0541

Ma Y, Adjamian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. (2013) 38:729–41. doi: 10.1016/j.immuni.2013.03.003

Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Décquier A, Gou et al. Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep. (2019) 27:2411–25.e9. doi: 10.1016/j.celrep.2019.04.091

Fong L, Hston A, Powderly JD, Sznol M, Heist RS, Choueiri TK, et al. Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer. Cancer Discov. (2020) 10:40–53. doi: 10.1158/2159-8290.CD-19-0980

Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. (2015) 162:1257–70. doi: 10.1016/j.cell.2015.08.015

Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, et al. Aspirin use and colorectal cancer survival according to tumor CD274 (Programmed cell death 1 ligand 1) Expression Status. J Clin Oncol. (2017) 35:1836–44. doi: 10.1200/JCO.2016.70.7547

Markosyan N, Li J, Sun YH, Richman LP, Lin JH, Yan F, et al. Tumor cell-intrinsic EPH2A suppresses anti-tumor immunity by regulating PTGS2 (COX-2). J Clin Invest. (2019) 130:3594–609. doi: 10.1172/JCI127755
Remodeling Intratumoral Immunity

Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JC, Aalbers AG, Sikorska K, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. (2020) 26:566–76. doi: 10.1038/s41591-020-0805-8

Pendergast GC, Smith C, Thomas S, Mandlik-Nayak L, Laury-Kleitkop L, Metz R, et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother. (2014) 63:721–35. doi: 10.1007/s00262-014-1549-4

Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-1L, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer. (2014) 2:3. doi: 10.1186/2051-1426-2-3

Holmgard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP.

Kather JN, Charoentong P, Suarez-Carmona M, Herpel E, Klupp F, Ulrich Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Concurrent EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T cell immunotherapy targeting CTLA-4. J Exp Med. (2018) 215:1839–402. doi: 10.1084/jem.20130066

Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301): KEYNOTE-252: a phase 3, randomised, double-blind study. Lancet Oncol. (2019) 20:1083–97. doi: 10.1016/S1470-2045(19)30274-8

Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Fung Z, Friedman DJ, et al. Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. Clin Cancer Res. (2017) 23:1665–77. doi: 10.1158/1078-0432.CCR-16-2677

Shirali RK, Ahmad S, Verma V, Zeng P, Ananth S, Gaur P, et al. Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis. Cancer Immunol Res. (2017) 5:755–66. doi: 10.1158/2326-6066.CIR-17-0292

Dong MB, Wang G, Chow RD, Ye L, Zhu L, Dai X, et al. Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T cells. Cell. (2019) 179:1189–204.e23. doi: 10.1016/j.cell.2019.07.044

Lizotte PH, Hong RL, Luster TA, Cavanaugh ME, Taus LJ, Wang S, et al. A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic t-lymphocyte tumor cell killing. Cancer Immunol Res. (2018) 6:1511–23. doi: 10.1158/2326-7445.AMC2018-4935

Khandelwal N, Breining M, Speck T, Michels T, Kreutzer C, Sorrentino A, et al. A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. EMBO Mol Med. (2015) 7:450–63. doi: 10.15252/emmm.201404414

Kather JN, Charoentong P, Suarez-Carmona M, Herpel E, Klupp F, Ulrich A, et al. High-throughput screening of combinatorial immunotherapies with patient-specific in silico models of metastatic colorectal cancer. Cancer Res. (2018) 78:1555–63. doi: 10.1158/0008-5472.CAN-18-1126

Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. (2017) 168:707–23. doi: 10.1016/j.cell.2017.01.017

Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. (2015) 7:279ra41. doi: 10.1126/scitranslmed.aab691

Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. (2013) 368:1365–6. doi: 10.1056/NEJMct1302338

Minor DR, Puzanov I, Callahan MK, Hug BA, Hoos A. Severe gastrointestinal toxicity with administration of tramebolimib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res. (2015) 28:611–2. doi: 10.1111/pcc.12383

Young A, Quandt Z, Bluestone JA. The balancing act between cancer immunity and autoimmunity in response to immunotherapy. Cancer Immunol Res. (2018) 6:1445–52. doi: 10.1158/2326-6066.CIR-18-0487

Du X, Liu M, Su J, Zhang P, Tang F, Ye P, et al. Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice. Cell Res. (2018) 28:433–47. doi: 10.1038/s41422-018-0012-z

Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. (2017) 28:368–76. doi: 10.1093/annonc/mdw443

Shah NJ, Al-Sbbool G, Blackburn M, Cook M, Belouali A, Liu SV, et al. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer. (2019) 7:353. doi: 10.1186/s41420-019-0771-1

Herbaux C, Gauthier J, Brice P, Drumez E, Yseaert L, Duyen H, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. (2017) 129:2471–8. doi: 10.1182/blood-2016-11-749556

Pai CS, Simons DM, Lu X, Evans M, Wei J, Wang YH, et al. Tumor-conditioned anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. J Clin Invest. (2019) 129:439–63. doi: 10.1172/JCI123391

Wu L, Seung E, Xu L, Rao E, Lord DM, Wei RR, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nature Cancer. (2020) 1:86–98. doi: 10.1038/s43018-019-0004-z

Kvarnhammar AM, Veitonnaki N, Hagerbrand K, Dahlman A, Smith KE, Fritzell S, et al. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. J Immunother Cancer. (2019) 7:103. doi: 10.1186/s41420-019-0570-8

Wang H, Mooney DJ. Biomaterial-assisted targeted modulation of immune cells in cancer treatment. Nat Mater. (2018) 17:761–72. doi: 10.1038/s41563-018-0147-9

Johnston RJ, Su LJ, Pinkney J, Critton D, Boyer E, Krishnakumar A, et al. VISTA is an acidic pH-selective ligand for PSGL-1. Nature. (2019) 574:565–70. doi: 10.1038/s41586-019-1674-5

Wang M, Wang J, Wong R, Jiao S, Wang S, Zhang J, et al. Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Aml58 glycosylation. Commun Biol. (2019) 2:239. doi: 10.1038/s42003-019-0642-9

Sun L, Li CW, Chung EM, Yang R, Kim YS, Park AH, et al. Targeting glycosylated PD-1 induces potent anti-tumor immunity. Cancer Res. (2020) 80:2298–310. doi: 10.1158/0008-5472.CAN-19-3133

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Copyright © 2020 Ngioy and Young. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.